Truqap

FDA
Biotech

FDA flags concerns for AZ's camizestrant, Truqap ahead of adcomm

The FDA has taken issue with camizestrant's trial design and questions the Truqap data's clinical meaningfulness.
Angus Liu Apr 28, 2026 2:47pm
FDA conference hall

FDA to end 9-month adcomm hiatus with review of AZ cancer drugs

Mar 6, 2026 11:16am
Businessman jumping over hurdle - stock photo viafilmsGetty Images

Relay breast cancer data tee up clash with AstraZeneca's Truqap

Sep 9, 2024 7:00am